Search
for
Sort by
Research 30 of 1000+
- A rare manifestation of STING-associated vasculopathy with onset in infancy: a case report
- The influence of interferon on healthy and diseased skin
- Rare and common manifestations of COVID‐19 in children
- Genetic Variants and Protective Immunity against SARS-CoV-2
- The Impact of Covid-19 Pandemic on the Clinical Course of Pediatric Skin Disorders: A Cross-Sectional Study
- Cutaneous manifestations associated with COVID-19 infection at a university hospital in eastern China
- LO-010 Relationship between the EULAR/ACR classification criteria and organ damage in systemic lupus erythematosus
- Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms
- The crosstalk of monocyte-neutrophil in hair follicles regulates neutrophil transepidermal migration in contact dermatitis
- Worldwide Clinical and Real-World Exposure to Baricitinib
- Dermatolojik Problemler ve COVID-19
- 034 Characterization of novel TMEM173 mutation causing a lupus- and SAVI-like phenotype, modified by polymorphisms in TMEM173 and IFIH1
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- Study of the Thyroid Profile of Patients with Alopecia
- Uncommon Presentation of Pityriasis Rubra Pilaris of the Scalp: Clinical, Trichoscopic, and Histopathologic Features and Review of the Literature
- The Spectrum of Cutaneous Manifestations in Lupus Erythematosus: A Comprehensive Review
- Characterization of novel TMEM173 mutation with additive IFIH1 risk allele
- The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience
- JAK Inhibitors in Down Syndrome: Alopecia Areata Resolution and Vitiligo Improvement with Baricitinib
- Hair follicle stem cell replication stress drives IFI16/STING-dependent inflammation in hidradenitis suppurativa
- Application of Baricitinib in Dermatology
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- JAK inhibition decreases the autoimmune burden in Down syndrome
- ABCD1 Gene Mutations: Mechanisms and Management of Adrenomyeloneuropathy
- JAK inhibition decreases the autoimmune burden in Down syndrome
- Skin, mucosa and nail findings in hospitalized pediatric patients with Coronavirus disease-2019 (COVID-19)
- Viruses, Variants, and Vaccines: How COVID-19 Has Changed the Way We Look at Skin
- The JAK/STAT signaling pathway: from bench to clinic
- Emerging Topical and Systemic JAK Inhibitors in Dermatology